Vamorolone - ReveraGen Biopharma

Drug Profile

Vamorolone - ReveraGen Biopharma

Alternative Names: VB-15; VBP-15

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ReveraGen BioPharma
  • Developer National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Neurological Disorders and Stroke; ReveraGen BioPharma; University of Pittsburgh
  • Class Anti-inflammatories; Antianaemics; Antiasthmatics; Corticosteroids; Glucocorticoids; Pregnatrienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy
  • Phase I Asthma; Cystic fibrosis; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Sickle cell anaemia
  • Discontinued Amyotrophic lateral sclerosis; Spinal muscular atrophy

Most Recent Events

  • 19 Jun 2018 ReveraGen BioPharma initiates the phase IIb VISION DMD trial for Duchenne Muscular Dystrophy (In children) in USA and Canada (PO) (NCT03439670)
  • 26 Apr 2018 ReveraGen BioPharma completes a phase IIa extension trial for Duchenne muscular dystrophy in USA, Canada, Australia, Israel, Sweden and United Kingdom (NCT02760277)
  • 01 Nov 2017 ReveraGen BioPharma completes a phase II trial in Duchenne muscular dystrophy (In children) in Canada, USA, Australia, Israel, Sweden, United Kingdom (PO) (NCT02760264)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top